Business
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results
CAMBRIDGE, Mass., May 14, 2025--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c359d4893a6c2e1cba85192a750170e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZhYWNopOTVuAevNuk1Ooeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c359d4893a6c2e1cba85192a750170e8","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/AOXgZcR63DPddRRgDhzfgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c359d4893a6c2e1cba85192a750170e8","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Corporate, Business and Product Development Highlights:","length":55,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds","length":78,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications","length":117,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Signed two licensing agreements for cannabinoid-COX-2 conjugate compounds, with potential to target joint pathologies, such as osteoarthritis and rheumatoid arthritis","length":166,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced closing of $5 million public offering","length":47,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":408,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., May 14, 2025--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.","length":416,"tagName":"p"},{"type":"text","content":""The first quarter of 2025 was highlighted by continued progress in the development of EB-003, our neuroplastogenic molecule that is designed to address difficult-to-treat mental health disorders," said Joseph Tucker, Ph.D....